Khan Meaghan, Mikhael Joseph
Division of Hematology - Oncology, Scottsdale, AZ, USA.
J Blood Med. 2010;1:21-31. doi: 10.2147/JBM.S6803. Epub 2010 Mar 23.
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder that is characterized by antibody-mediated platelet destruction and decreased platelet production. ITP and its treatments have been recognized to cause diminished quality of life in those afflicted with this illness on levels comparable to other chronic diseases. The disease can be self-limiting, but in adults it often is a chronic process requiring medical intervention to maintain appropriate platelet counts and to reduce bleeding events. Many patients go on to develop disease that is refractory to current interventions. Historically, the aim of treatment has been focused on reducing the amount of antibody-mediated destruction but newer therapies have centered on the decreased platelet production. Two new medications that target production of platelets have recently been USA, Food and Drug Administration (FDA) approved for the treatment of chronic relapsing ITP. Here, we provide an overview of ITP and a comprehensive review of the newest therapies aimed at the stimulation of platelet production.
免疫性血小板减少性紫癜（ITP）是一种自身免疫性疾病，其特征是抗体介导的血小板破坏和血小板生成减少。ITP及其治疗方法已被认为会导致患者生活质量下降，其程度与其他慢性疾病相当。这种疾病可能是自限性的，但在成年人中通常是一个慢性过程，需要医学干预以维持适当的血小板计数并减少出血事件。许多患者会发展为对当前干预措施难治的疾病。从历史上看，治疗的目标一直集中在减少抗体介导的破坏量，但新的疗法则集中在血小板生成减少方面。最近，美国食品药品监督管理局（FDA）批准了两种针对血小板生成的新药用于治疗慢性复发性ITP。在此，我们概述了ITP，并全面综述了旨在刺激血小板生成的最新疗法。
